Login
Home / CHSYF : OTC
Follow Compare
AI Analysis Fundamentals Valuation Video Analysis News Similar
Quarterly Quarterly (TTM) Annually

AI Analysis

Log in to generate an AI summary for this stock.

Log in to generate a MOAT report for this stock.

Log in to generate an earnings report for this stock.

Log in to generate an operating leverage report for this stock.

Log in to generate a management report for this stock.

Log in to generate a valuation report for this stock.

China Medical System Holdings Limited

$1.57 +$0.22 (+16.30%)
OTC · 11 Sep 2026 20:00 UTC
Previous Close
$1.57
Day Range
$0.93$1.57
Year Range
$0.93$1.57
Market Cap
3.8B
AVG Volume
25
Trailing/Forward PE
15.16/1.59
PEG ratio
0.97
Dividend Yield
3.12%
Next Earnings Date
2027-03-16
Primary Exchange
Other OTCUS
Revenue (CNY)
02B4B6B21 Q422 Q222 Q423 Q223 Q424 Q224 Q425 Q225 Q426 Q2
Net Income (CNY)
0500M1B1.5B2B21 Q422 Q222 Q423 Q223 Q424 Q224 Q425 Q225 Q426 Q2
Operating Income (CNY)
0500M1B1.5B2B21 Q422 Q222 Q423 Q223 Q424 Q224 Q425 Q225 Q426 Q2
EBITDA (CNY)
0500M1B1.5B2B21 Q422 Q222 Q423 Q223 Q424 Q224 Q425 Q225 Q426 Q2
Cash Flows (CNY)
-1B01B2B3B21 Q422 Q222 Q423 Q223 Q424 Q224 Q425 Q225 Q426 Q2
EPS (CNY)
00.20.40.60.821 Q422 Q222 Q423 Q223 Q424 Q224 Q425 Q225 Q426 Q2
Expenses (CNY)
01B2B3BR&DSG&ACapex21 Q422 Q222 Q423 Q223 Q424 Q224 Q425 Q225 Q426 Q2
Cash & Debt (CNY)
02B4B6B8BCashLong Term DebtShort Term Debt21 Q422 Q222 Q423 Q223 Q424 Q224 Q425 Q225 Q426 Q2
Debt ratios
-1.5-1-0.5021 Q422 Q222 Q423 Q223 Q424 Q224 Q425 Q225 Q426 Q2
Margins
0%20%40%60%80%21 Q422 Q222 Q423 Q223 Q424 Q224 Q425 Q225 Q426 Q2
Return on Capital
0%5%10%15%21 Q422 Q222 Q423 Q223 Q424 Q224 Q425 Q225 Q426 Q2
Shares Outstanding
01B2B3B21 Q422 Q222 Q423 Q223 Q424 Q224 Q425 Q225 Q426 Q2
Dividends (CNY)
00.020.040.06Apr 22Sep 22May 23Sep 23May 24Aug 24Apr 25Sep 25Apr 26Sep 26
Book Value Per Share (CNY)
0246821 Q422 Q222 Q423 Q223 Q424 Q224 Q425 Q225 Q426 Q2
Total Assets (CNY)
05B10B15B20B21 Q422 Q222 Q423 Q223 Q424 Q224 Q425 Q225 Q426 Q2
PE Ratio
246810med 7.12Dec 24Apr 25Jul 25Oct 25Feb 26May 26Sep 26
Free Cash Flow Yield
0%10%20%30%40%med 12.7%Dec 24Apr 25Jul 25Oct 25Feb 26May 26Sep 26
Price to Sales
0.7511.251.51.752med 1.44Dec 24Apr 25Jul 25Oct 25Feb 26May 26Sep 26
EV/EBITDA
123456med 4.11Dec 24Apr 25Jul 25Oct 25Feb 26May 26Sep 26
Price/Operating Cashflow
2.557.51012.515med 7.73Dec 24Apr 25Jul 25Oct 25Feb 26May 26Sep 26
Price to Book
0.811.21.41.61.8med 1.28Dec 24Apr 25Jul 25Oct 25Feb 26May 26Sep 26
China Medical System Holdings Limited
CHSYF
Stockpicker

Video analysis: CHSYF

All videos

No video analysis for this stock yet. Request one from our team.

Your email is used only to follow up on this request. We do not add you to marketing lists. Privacy Policy

News: CHSYF

CMS(867.HK/8A8.SG): Innovative Drug Lumirix® Approved in China for Additional Indication of Atopic Dermatitis (AD)

globenewswire.com · 3 Sep 2026

CMS(867.HK/8A8.SG): Innovative Drug Lumirix® Approved in China for Additional Indication of Atopic Dermatitis (AD)

SHENZHEN, CHINA, Sept. 03, 2026 (GLOBE NEWSWIRE) -- China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that its subsidiary, Dermavon Holdings Limited (“Dermavon”, an innovative pharmaceutical company specialized in skin health which is applying for a separate listing on the Main Board of The Stock Exchange of Hong Kong Limited) received the approval from the National Medical Products Administration of China (NMPA) for the New Drug Application (NDA) of ruxolitinib phosphate cream (Lumirix®) for the treatment of mild to moderate atopic dermatitis (“AD”) on 2 September 2026. The drug registration certificate was obtained on 3 September 2026. The product is indicated for the topical short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised adult and pediatric patients 2 years of age and older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.

Similar companies

Disclaimer: The historical data presented on this platform is provided by Financial Modeling Prep. Stock Picker is a platform for informational purposes only and does not provide financial advice. Users are encouraged to conduct their own research and consult with a qualified financial advisor before making investment decisions.